Aberrant micro RNA and epigenetic network are associated with progression from MGUS to multiple myeloma

[Rinshō ketsueki] The Japanese journal of clinical hematology
Hiroshi Handa

Abstract

In recent years, attention has been drawn to aberrant epigenetics as well as coding gene mutations in cancers. DNA methylation, histone acetylation and methylation, and micro RNA (miRNA) are included in the field of epigenetics. miRNAs are small RNAs of only 19-25 bases in length which do not encode protein but do they control gene expression by destroying mRNA or inhibiting translation. In multiple myeloma (MM), several miRNA expressions were markedly decreased, while in contrast their target genes, associated with apoptosis, the cell cycle and DNA methylation, were markedly increased. Negative correlations were found between miRNA and target genes expressions. The miR-34 family in itself was methylated, and expression was epigenetically controlled. miRNA and other epigenetic mechanisms underlie network formation, thought to be associated with MM progression. Thus, examining miRNA of MM is currently an important issue in terms of predicting patient outcomes and developing novel therapies.

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.